ResMed, one of the dominant players in the sleep-disorder market, has signed a definitive deal to buy Minnesota-based MatrixCare to augment its expanding software-as-a-service business with MatrixCare's electronic health record platform for long-term care settings.
ResMed Inc. is continuing to invest aggressively in its "software-as-a-service" offerings with the addition of MatrixCare, a provider of long-term post-acute care software that currently serves more than 15,000 skilled-nursing, life-plan community, senior-living, and private-duty care facilities.
The acquisition, announced Nov. 5, will cost San Diego-based ResMed $750m financed primarily through its credit facility. The price is...
When a large medtech company sets up a venture fund, it typically invests in technologies that are adjacent to its pre-existing portfolio. Intuitive Surgical’s approach is different.
Spain has one of the highest incarceration rates in Europe, with 160 individuals imprisoned per 100,000 residents. In 2020, 43,494 people were incarcerated in facilities not managed by regional health authorities — essentially all regions except Catalonia, the Basque Country, and Navarra.
Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.
This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.
